Literature DB >> 21859275

Guidelines for aerosol devices in infants, children and adults: which to choose, why and how to achieve effective aerosol therapy.

Arzu Ari1, James B Fink.   

Abstract

Multiple types of aerosol devices are commonly used for the administration of medical aerosol therapy to patients with pulmonary diseases. All of these devices have been shown to be effective in trials where they are used correctly. However, failure to operate any of these devices properly has been associated with poor clinical response and limited patient adherence to therapy. Therefore, the selection of the best aerosol device for the individual patient is very important for optimizing the results of medical aerosol therapy. This article presents the rationale for selecting the most appropriate aerosol device to administer inhaled drugs in specific patient populations, with emphasis on patient-, drug-, device- and environment-related factors and with a comparison between the available devices. The following recommendations for the selection of the 'best' aerosol device for each patient population are intended to help clinicians gain a clear understanding of the specific issues and challenges so that they can optimize aerosol drug delivery and its therapeutic outcomes in patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21859275     DOI: 10.1586/ers.11.49

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  11 in total

Review 1.  A path to successful patient outcomes through aerosol drug delivery to children: a narrative review.

Authors:  Arzu Ari
Journal:  Ann Transl Med       Date:  2021-04

Review 2.  Administration of dry powders during respiratory supports.

Authors:  Wei-Ren Ke; Rachel Yoon Kyung Chang; Philip Chi Lip Kwok; Patricia Tang; Lan Chen; Donghao Chen; Hak-Kim Chan
Journal:  Ann Transl Med       Date:  2021-04

3.  Characterizing the Effects of Nasal Prong Interfaces on Aerosol Deposition in a Preterm Infant Nasal Model.

Authors:  Karl Bass; Mohammad A M Momin; Connor Howe; Ghali Aladwani; Sarah Strickler; Arun V Kolanjiyil; Michael Hindle; Robert M DiBlasi; Worth Longest
Journal:  AAPS PharmSciTech       Date:  2022-04-19       Impact factor: 3.246

4.  In Vitro Analysis of Nasal Interface Options for High-Efficiency Aerosol Administration to Preterm Infants.

Authors:  Connor Howe; Mohammad A M Momin; Karl Bass; Ghali Aladwani; Serena Bonasera; Michael Hindle; Philip Worth Longest
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2022-02-14       Impact factor: 3.440

Review 5.  Drug delivery interfaces: A way to optimize inhalation therapy in spontaneously breathing children.

Authors:  Arzu Ari
Journal:  World J Clin Pediatr       Date:  2016-08-08

Review 6.  Advanced human-relevant in vitro pulmonary platforms for respiratory therapeutics.

Authors:  Arbel Artzy-Schnirman; Sivan Arber Raviv; Ofri Doppelt Flikshtain; Jeny Shklover; Netanel Korin; Adi Gross; Boaz Mizrahi; Avi Schroeder; Josué Sznitman
Journal:  Adv Drug Deliv Rev       Date:  2021-07-29       Impact factor: 15.470

7.  A Handling Study to Assess Use of the Respimat(®) Soft Mist™ Inhaler in Children Under 5 Years Old.

Authors:  Wolfgang Kamin; Marion Frank; Sabine Kattenbeck; Petra Moroni-Zentgraf; Herbert Wachtel; Stefan Zielen
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-04-06       Impact factor: 2.849

8.  Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.

Authors:  David Prime; Wilfried de Backer; Melanie Hamilton; Anthony Cahn; Andrew Preece; Dennis Kelleher; Amanda Baines; Alison Moore; Noushin Brealey; Jackie Moynihan
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2015-09-15       Impact factor: 2.849

Review 9.  Fundamentals of aerosol therapy in critical care.

Authors:  Jayesh Dhanani; John F Fraser; Hak-Kim Chan; Jordi Rello; Jeremy Cohen; Jason A Roberts
Journal:  Crit Care       Date:  2016-10-07       Impact factor: 9.097

Review 10.  Patients' perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®).

Authors:  Pieter Nicolaas Richard Dekhuijzen; Federico Lavorini; Omar S Usmani
Journal:  Patient Prefer Adherence       Date:  2016-08-18       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.